Xilio Therapeutics/XLO

$1.13

-4.24%
-
1D1W1MYTD1YMAX

About Xilio Therapeutics

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Its product pipeline includes XTX101, XTX301, XTX202, XTX501, and tumor-activated bispecific molecules and immune cell engager molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.

Ticker

XLO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Rene Russo

Employees

73

Headquarters

Waltham, United States
Website
xiliotx.com

XLO Metrics

BasicAdvanced
$44M
Market cap
-
P/E ratio
-$2.78
EPS
-
Beta
-
Dividend rate
$44M
$3.25
$0.49
1.2M
3.016
9.002
-131.89%
-76.37%
-107.25%
-93.74%
0.885
1.183
13.71%

What the Analysts think about XLO

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 2 analysts.
386.73% upside
High $6.00
Low $5.00
$1.13
Current price
$5.50
Average price target

XLO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
NaN%
Net income
-$18M
5.39%
Profit margin
0%
NaN%

XLO Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.83
-$0.70
-$0.61
-$0.64
-
Expected
-$0.89
-$0.87
-$0.81
-$0.64
-$0.11
Surprise
-6.29%
-19.31%
-24.46%
0%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Xilio Therapeutics stock?

Xilio Therapeutics (XLO) has a market cap of $44M as of May 13, 2024.

What is the P/E ratio for Xilio Therapeutics stock?

The price to earnings (P/E) ratio for Xilio Therapeutics (XLO) stock is 0 as of May 13, 2024.

Does Xilio Therapeutics stock pay dividends?

No, Xilio Therapeutics (XLO) stock does not pay dividends to its shareholders as of May 13, 2024.

When is the next Xilio Therapeutics dividend payment date?

Xilio Therapeutics (XLO) stock does not pay dividends to its shareholders.

What is the beta indicator for Xilio Therapeutics?

Xilio Therapeutics (XLO) does not currently have a Beta indicator.

What is the Xilio Therapeutics stock price target?

The target price for Xilio Therapeutics (XLO) stock is $5.5, which is 386.73% above the current price of $1.13. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Xilio Therapeutics stock

Buy or sell Xilio Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing